Literature DB >> 30419264

The genetics, structure and function of the M1 aminopeptidase oxytocinase subfamily and their therapeutic potential in immune-mediated disease.

Aimee L Hanson1, Craig J Morton2, Michael W Parker2, Darrell Bessette3, Tony J Kenna3.   

Abstract

The oxytocinase subfamily of M1 aminopeptidases plays an important role in processing and trimming of peptides for presentation on major histocompatibility (MHC) Class I molecules. Several large-scale genomic studies have identified association of members of this family of enzymes, most notably ERAP1 and ERAP2, with immune-mediated diseases including ankylosing spondylitis, psoriasis and birdshot chorioretinopathy. Much is now known about the genetics of these enzymes and how genetic variants alter their function, but how these variants contribute to disease remains largely unresolved. Here we discuss what is known about their structure and function and highlight some of the knowledge gaps that affect development of drugs targeting these enzymes.
Copyright © 2018 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aminopeptidase; Antigen presentation; Autoimmunity; Inhibitor

Mesh:

Substances:

Year:  2018        PMID: 30419264     DOI: 10.1016/j.humimm.2018.11.002

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  8 in total

1.  Inhibitor-Dependent Usage of the S1' Specificity Pocket of ER Aminopeptidase 2.

Authors:  Anastasia Mpakali; Dimitris Georgiadis; Efstratios Stratikos; Petros Giastas
Journal:  ACS Med Chem Lett       Date:  2022-01-13       Impact factor: 4.345

2.  ERAPs Reduce In Vitro HIV Infection by Activating Innate Immune Response.

Authors:  Irma Saulle; Ivana Marventano; Marina Saresella; Claudia Vanetti; Micaela Garziano; Claudio Fenizia; Daria Trabattoni; Mario Clerici; Mara Biasin
Journal:  J Immunol       Date:  2021-02-22       Impact factor: 5.422

3.  Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues.

Authors:  Peter Kubiniok; Ana Marcu; Leon Bichmann; Leon Kuchenbecker; Heiko Schuster; David J Hamelin; Jérôme D Duquette; Kevin A Kovalchik; Laura Wessling; Oliver Kohlbacher; Hans-Georg Rammensee; Marian C Neidert; Isabelle Sirois; Etienne Caron
Journal:  iScience       Date:  2022-01-18

Review 4.  To Be or Not to Be: The Case of Endoplasmic Reticulum Aminopeptidase 2.

Authors:  Piotr Kuśnierczyk
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

5.  ERAP1 binds peptide C-termini of different sequences and/or lengths by a common recognition mechanism.

Authors:  Lufei Sui; Hwai-Chen Guo
Journal:  Immunobiology       Date:  2021-07-04       Impact factor: 3.152

6.  Discovery and Optimization of a Series of Benzofuran Selective ERAP1 Inhibitors: Biochemical and In Silico Studies.

Authors:  Safia Deddouche-Grass; Cyrielle Andouche; Felix Bärenz; Célia Halter; Arnaud Hohwald; Louison Lebrun; Nathalie Membré; Renaud Morales; Nicolas Muzet; Matthieu Poirot; Morgane Reynaud; Véronique Roujean; Fabienne Weber; André Zimmermann; Rama Heng; Nicolas Basse
Journal:  ACS Med Chem Lett       Date:  2021-06-04       Impact factor: 4.632

7.  Endoplasmic Reticulum Associated Aminopeptidase 2 (ERAP2) Is Released in the Secretome of Activated MDMs and Reduces in vitro HIV-1 Infection.

Authors:  Irma Saulle; Salomè Valentina Ibba; Enrica Torretta; Cecilia Vittori; Claudio Fenizia; Federica Piancone; Davide Minisci; Elisa Maria Lori; Daria Trabattoni; Cecilia Gelfi; Mario Clerici; Mara Biasin
Journal:  Front Immunol       Date:  2019-07-16       Impact factor: 7.561

8.  The Multifaceted Nature of Aminopeptidases ERAP1, ERAP2, and LNPEP: From Evolution to Disease.

Authors:  Fabiana Paladini; Maria Teresa Fiorillo; Valentina Tedeschi; Benedetta Mattorre; Rosa Sorrentino
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.